B., Fu, X., Wu, Y., Li, L., Smith, J
A separate late-stage cardiovascular outcomes trial is ongoing
Synovium derived mesenchymal stromal cells (Sy-MSCs): a promising therapeutic paradigm in the management of knee osteoarthritis
Depending on your lab values, the frequency could range from weekly to monthly until your levels fall back into the normal ranges
In the Phase 2 obesity data the weight curve was still trending downward at 48 weeks, so a genuine plateau at a tolerated maintenance dose may simply reflect the body settling toward a new set point rather than the protocol failing
Most patients experience no adverse effects, and when present, theyre typically mild and transient including temporary digestive changes as the gut adjusts, minor nausea (usually resolving within days), or altered bowel patterns during initial therapy